Pivot | Jotup

Evenflo Unveils the Pivot Xplore™ Dreamz All-Terrain Stroller Wagon with Bassinet Insert

Retrieved on:

Monday, January 29, 2024

Evenflo, designer, manufacturer, and marketer of infant and children’s products, today announced the Pivot Xplore™ Dreamz All-Terrain Stroller Wagon with Bassinet Insert.

Key Points:

Evenflo, designer, manufacturer, and marketer of infant and children’s products, today announced the Pivot Xplore™ Dreamz All-Terrain Stroller Wagon with Bassinet Insert.
Like Evenflo’s popular Pivot Xplore™ All-Terrain Stroller Wagon, Dreamz offers the same functionality that parents love now with a new bassinet insert, designed for a child from 6 months up to 33 lbs., that lets your little one take a break from the action comfortably.
The new stroller wagon accommodates up to two children aged 6 months to 5 years, with each seat holding a child up to 55 lbs.
With the new Pivot Xplore™ Dreamz, parents can now seamlessly transition their children from exploration to relaxation,” said Sharon Ruggieri, Senior Director of Product Management at Evenflo.

Announcing the recipients of the 2024 St. Louis Titan 100

Retrieved on:

Saturday, January 27, 2024

RIA, The Armory, Pivot, Armory, Environment, Creativity, Organization, Growth, Management

ST. LOUIS, Jan. 27, 2024 /PRNewswire-PRWeb/ -- Titan CEO and headline sponsor Wipfli LLP are pleased to announce Justin Woodard, CEO & President, Woodard Cleaning & Restoration as a 2024 St. Louis Titan 100. The Titan 100 program recognizes the Top 100 CEOs & C-level executives in St. Louis. They are the area's most accomplished business leaders in their industry using criteria that includes demonstrating exceptional leadership, vision, and passion. Collectively the 2024 St. Louis Titan 100 and their companies employ upwards of 129,000 individuals and generate over $31 billion in annual revenues. This year's honorees will be published in a limited-edition Titan 100 book and profiled exclusively online. They will be honored at an awards ceremony on April 18th, 2024, and have the opportunity to interact and connect multiple times throughout the year with their fellow Titans.

Key Points:

Honorees will be featured in a Titan 100 book, profiled online, and celebrated at an awards ceremony on April 18th, 2024.
ST. LOUIS, Jan. 27, 2024 /PRNewswire-PRWeb/ -- Titan CEO and headline sponsor Wipfli LLP are pleased to announce Justin Woodard, CEO & President, Woodard Cleaning & Restoration as a 2024 St. Louis Titan 100.
The Titan 100 program recognizes the Top 100 CEOs & C-level executives in St. Louis.
Collectively the 2024 St. Louis Titan 100 and their companies employ upwards of 129,000 individuals and generate over $31 billion in annual revenues.

Kara Swisher to receive CJF Tribute Award

Retrieved on:

Wednesday, January 17, 2024

Managing editor, Recode, The Washington Post, CJF, Culture, Pivot, History, Fairmont Royal York, All Things Digital, Canadian Journalism Foundation, Blog, The New York Times, CTV, Tribute, All, Human, NEWS, Nieman Fellowship

TORONTO, Jan. 17, 2024 /CNW/ - The Canadian Journalism Foundation (CJF) is delighted to announce it will honour media icon Kara Swisher with its annual CJF Tribute, in recognition of her trailblazing journalism career, fearlessly speaking truth to power within the technology industry.

Key Points:

TORONTO, Jan. 17, 2024 /CNW/ - The Canadian Journalism Foundation (CJF) is delighted to announce it will honour media icon Kara Swisher with its annual CJF Tribute, in recognition of her trailblazing journalism career, fearlessly speaking truth to power within the technology industry.
The annual CJF Tribute recognizes media luminaries who have made an exceptional journalistic impact on the international stage.
The Tribute will be presented at the CJF annual Awards evening on June 12 at the Fairmont Royal York in Toronto.
The CJF will provide a copy to all attendees at the CJF Awards evening.

Kane Biotech Announces Amendment to its Credit Facility

Retrieved on:

Thursday, December 28, 2023

Pivot, Line of credit, TSX Venture Exchange, KNE, Credit

WINNIPEG, Manitoba, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 20, 2023, the Company and Pivot I Financial Limited Partnership (“Pivot”) entered into a definitive agreement to amend the terms of the Company’s amended and restated credit facility between Pivot and the Company dated August 31, 2021, as amended (the “Credit Facility”) by extending the maturity date of the Credit Facility from November 30, 2023 to March 31, 2023.

Key Points:

WINNIPEG, Manitoba, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 20, 2023, the Company and Pivot I Financial Limited Partnership (“Pivot”) entered into a definitive agreement to amend the terms of the Company’s amended and restated credit facility between Pivot and the Company dated August 31, 2021, as amended (the “Credit Facility”) by extending the maturity date of the Credit Facility from November 30, 2023 to March 31, 2023.
In addition, the parties agreed that from December 1, 2023 until maturity, interest accrued on each advance under the Credit Facility thereafter shall be payable monthly in arrears rather than being added to the principal amount of the Credit Facility and repaid at maturity.
“I would like to thank Pivot for their ongoing support of Kane,” said Ray Dupuis, Chief Financial Officer.
“The extension of the Credit Facility maturity date will allow us to work toward closing on a binding share purchase agreement with respect to the offer it has received for its interest in STEM Animal Health, which the Company announced on December 20, 2023.”
The amendment to the Credit Facility remains subject to the final approval of the TSX Venture Exchange.

Kane Biotech Receives Offer for its Interest in STEM Animal Health

Retrieved on:

Wednesday, December 20, 2023

Partnership, Dermatology, TSX Venture Exchange, Sale, Pivot, Health, KNE, Biofilm

WINNIPEG, Manitoba, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 19, 2023, it signed a non-binding offer for the sale of its interest in STEM Animal Health Inc. (“STEM”).

Key Points:

WINNIPEG, Manitoba, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 19, 2023, it signed a non-binding offer for the sale of its interest in STEM Animal Health Inc. (“STEM”).
“In 2018, when I joined as CEO, Kane made the strategic decision to continue to build Kane’s animal health portfolio, while expanding into advanced wound care” said Marc Edwards, Chief Executive Officer of Kane Biotech.
These actions have created real value within STEM.”
The terms of the offer remain confidential but specify that Kane will sell its ownership of STEM.
“We are pleased to receive an offer that reflects the full value we see in STEM,” said Philip Renaud, Chairman of the Board of Kane.

Kane Biotech Announces Improved Third Quarter 2023 Financial Results

Retrieved on:

Tuesday, November 28, 2023

SAWC, Private, Sale, Credit, Government, FDA, Pivot, Blood, Financial statement, KNE, PHMB, Symposium, Wound healing

WINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results.

Key Points:

WINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results.
Gross profit for the third quarter of 2023 was $315,265, an increase of 17% compared to $269,740 for the quarter ended September 30, 2022.
Detailed financial information about Kane Biotech can be found in its September 30, 2023 Financial Statements and Management Discussion and Analysis on SEDAR and the Company’s website.
On November 16, 2023, Kane Biotech announced that Dr. John Coleman had been appointed to the Board of Directors of Kane Biotech effective immediately.

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

Retrieved on:

Thursday, December 14, 2023

Yanay Ofran, Ph.D., CEO and founder of Biolojic Design: "We are excited about the opportunity to work with Teva and bring hope to patients.

Key Points:

Yanay Ofran, Ph.D., CEO and founder of Biolojic Design: "We are excited about the opportunity to work with Teva and bring hope to patients.
The potential therapy we designed for Atopic Dermatitis and Asthma is another example of how AI can revolutionize drug development.
Under the terms of the agreement, Teva will receive exclusive rights to develop, manufacture and commercialize BD9 worldwide.
Biolojic is also eligible to receive tiered royalties in the mid-single to low-double digit on product sales should Teva successfully commercialize a therapy.

Pivot Energy Partners with Tapestry, Inc. Enabling New Clean Energy and Increased Community Investment

Retrieved on:

Tuesday, December 12, 2023

Sustainability, NYSE, Organization, Kate Spade, Workforce, Wind, Solar energy, Farm, REC, Guarantee of origin, Partnership, Growth, Electricity, Kilowatt-hour, ESG, Renewable energy, Coach, Pivot, Tapestry

CHICAGO, Dec. 12, 2023 /PRNewswire/ -- Leading national renewable energy provider Pivot Energy is proud to announce it is developing six community solar projects in Illinois, totaling 33 megawatts (MWdc), with Tapestry, Inc. (NYSE: TPR), a house of iconic accessories and lifestyle brands consisting of Coach, Kate Spade, and Stuart Weitzman. Tapestry has committed to purchasing 15 years of Impact Renewable Energy Credits (RECs) produced by the projects, which will produce more than 50,000 megawatt hours (MWh) per year with a total estimated 750,000 MWh over the course of 15 years. This commitment helps enable new renewable energy to be developed in Illinois. Additionally, the two companies will invest $2,000 per MW built, or $66,000 total, in local community organizations.

Key Points:

What makes this project unique is the multifaceted opportunity to create measurable impact growth of solar energy.
In Pivot and Tapestry's case, the impact is three-fold – new clean energy, community investments, and energy burden relief.
Pivot Energy is committed to accelerating the transition to clean energy and positively impacting local communities.
By supporting clean energy projects and engaging with local communities, Tapestry is demonstrating its commitment to renewable energy and sustainable operations in the fashion industry.

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

Retrieved on:

Tuesday, November 7, 2023

Biotechnology, Pharmaceutical, Health, Knowledge, NYSE, CDMO, Teva Active Pharmaceutical Ingredients, TEVA, Pivot, Growth, Agro, API, P&L, TASE, Patient, Piramal, Generic drug, Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api).

Key Points:

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api).
Richard Francis, Teva’s President and CEO said: “I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business.
Having led the former Teva api and Biologics Operations organization at Teva from 2014 to 2018, Dr. Ananth has a deep understanding of Teva’s API business.
Dr. Ananth stated, “I am very excited to return to Teva to lead the API business, and to join my esteemed colleagues and teams at Teva api – old and new.

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

Retrieved on:

Wednesday, October 4, 2023

Inflammatory bowel disease (IBD) is the term for two conditions -- Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract. Prolonged inflammation results in damage to the GI tract. The common symptoms for both conditions are persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. An estimated ~10 million people worldwide live with IBD.

Key Points:

Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A.
Inflammatory bowel disease (IBD) is the term for two conditions -- Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract.
Teva will hold an investor call and live webcast today (Wednesday, October 4, 2023) at 8:00 a.m.